Biological treatment strategies of depression - Psychopharmacology and non-pharmacological methods;Psychopharmakologie und andere biologische verfahren zur therapie der depression

Therapeutische Umschau

Volumn 67, Issue 11, 2010, Pages 585-591

  Hatzinger, Martin ^a  

^a Erwachsenenpsychiatrie Psychiatrische Dienste   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AGOMELATINE; AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DIBENZEPIN; DOXEPIN; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; HYPERICUM PERFORATUM EXTRACT; IMIPRAMINE; MAPROTILINE; MIANSERIN; MILNACIPRAN; MIRTAZAPINE; MOCLOBEMIDE; NORTRIPTYLINE; PAROXETINE; REBOXETINE; SERTRALINE; TRAZODONE; VENLAFAXINE;

DEPRESSION; DRUG EFFICACY; ELECTROCONVULSIVE THERAPY; EVIDENCE BASED MEDICINE; HUMAN; REVIEW; SEASONAL AFFECTIVE DISORDER; SLEEP DEPRIVATION; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT RESPONSE;

ANTIDEPRESSIVE AGENTS; COMBINED MODALITY THERAPY; DEPRESSIVE DISORDER; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; HUMANS; HYPERICUM; LONG-TERM CARE; PHYTOTHERAPY; PLANT EXTRACTS; PSYCHOTHERAPY; RECURRENCE;

EID: 78149309697     PISSN: 00405930     EISSN: None     Source Type: Journal    
DOI: 10.1024/0040-5930/a000100     Document Type: Review

References (10)

1. WHO Weltgesundheitsorganisation. Internationale Klassifikation psychischer Störungen. ICD-10 Kapitel V (F) Klinisch-diagnostische Leitlinien In: Dilling H, Mombour W, Schmidt MH, Hrsg. ICD-10. Bern Göttingen Toronto: Verlag Hans Huber, 1991, 118-140.
2. S3-Leitlinie/Nationale Versorgungsleitlinie "Unipolare Depression" der Deutschen Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde (DGPPN) 2009 (http:// www.versorgungsleitlinien.de).
3. Bauer M, Bschor T, Pfennig A, Whybrow P, Angst J, Versiani M, Möller HJ, Updated WFSBP Guidelines for the Biological Treatment of Unipolar Depressive Disorders in Primary Care World Journal of Biological Psychiatry, 2007; 8: 67-104.
4. Kupfer DJ. Long-term treatment of depression. J Clin Psychiatry 1991; 52(Suppl): 28-34.
5. Holsboer-Trachsler E, Holsboer F. Antidepressiva. In: Holsboer F, Gründer G, Benkert O, Hrsg. Handbuch der Psychopharmakotherapie. Springer Verlag Heidelberg 2008: 517-553 (ISBN 978-540-20475-6).
6. Linde K, Mulrow CD, Berner M, Egger M. St John's wort for depression. Cochrane Database Syst Rev 2005; 2: CD000448.
7. Lam RW, Kennedy SH, Grigoriadis S, McIntyre RS, Milev R, Ramasubbu R, Parikh SV, Patten SB, Ravindran AV. Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. Journal of Affective Disorders 2009; 117: S26-43.
8. Tranter R, O'Donovan C, Chandarana P, Kennedy S. Prevalence and outcome of partial remission in depression. J Psychiatry Neurosci 2002; 27: 241-7.
9. Bauer M, Crossley NA, Gerber S, Bschor T. The acute antidepressive effects of lithium: from monotherapy to augmentation. In: Bauer M, Grof P, Müller-Oerlinghausen, eds. Lithium in Neuropsychiatry - The Comprehensive Guide. Abingdon: Informa Healthcare, 2006:109-28.
10. Herwig U, Fallgatter AJ, Höppner J, Eschweiler GW, Kron M, Hajak G et al. Antidepressant effects of augmentative transcranial magnetic stimulation: randomised multicentre trial. Br J Psychiatry 2007; 191: 441-448.